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What’s Contrasting Contrast?
I read with interest the recently published paper by Greupner et al.
(1), and would like to comment on the surprising absence of
contrast echocardiography among the tested methods for volume
and ejection fraction measurement.
At least 2 previously published studies, which were not appro-
priately referenced and discussed in the paper, conducted in wider
samples (120 and 50 subjects, respectively), demonstrated that
both 2- and 3-dimensional echocardiograms benefit significantly
from contrast administration in terms of accuracy and reduced
interobserver variability compared with standard echocardiography
and cardiac magnetic resonance, as long as volumes and ejection
fraction measurements are considered (2,3).
Furthermore, the study byHoffmann et al. (2) was amulticenter study,
and demonstrated that the interobserver variability of contrast echocar-
diography (both mean percentage of error and intraclass correlation) for
ejection fraction was even lower than that of cardiac magnetic resonance,
which is usually considered the reference method.
Why was there no testing of echocardiography with contrast,
which is cheap, widely available, and approved for endocardial
border enhancement indication?
A slightly modified old-fashioned ultrasound technique has the
potential to outperform more costly, glittering, and technically
demanding techniques, or at least it should be given a fair chance.
This happens in front of the widespread urge to cut the world
health costs, and a clear and common sense European Union
European Atomic Energy Community directive, which compels
the use of nonradiating diagnostic methods in medicine when they
can be used in substitution of methods using ionizing radiations.
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Reply
We found the comments of Dr. Gaibazzi very thoughtful. We
certainly agree that echocardiography should be the “first line”
technique for evaluation of left ventricular function because it is widely
available, easily done, very cost efficient, and does not require ionizing
radiation. Furthermore, contrast media are a possible way to improve
the diagnostic performance of echocardiography (1,2). However,
there is also evidence that computed tomography (CT) shows better
reproducibility and accuracy than contrast-enhanced (CE) echocardi-
ography (3,4) and may be favored in certain patients (e.g., those with
deformed ventricular anatomy).
To address this issue, we also included 2-dimensional (2D) CE
echocardiography in our study. To stay as close to everyday clinical
practice, we left the decision to administer contrast media to the
cardiologist depending on the quality of the acoustic window for
echocardiography. Only 7 of 36 patients underwent 2D CE
echocardiography. In this, albeit small, subgroup of our study,
there was no significant difference in the Bland-Altman analysis of
ejection fraction (EF) and stroke volume for CT, 2D echocardio-
graphy and 2D CE echocardiography compared with magnetic
resonance imaging (MRI) as the reference standard. We found
significantly smaller end-diastolic volume (EDV) and end-systolic
volume (ESV) in 2D echocardiography and 2D CE echocardio-
graphy compared with MRI as the reference standard (Table 1). How-
ever, only 2D echocardiography showed significantly larger limits of
agreement for EDV than CT. In addition, although there was a trend
toward smaller limits of agreement for 2D CE echocardiography, we
found no significant improvement compared with 2D echocardiography.
Therefore, our small cohort indicates that contrast improves the
accuracy of echocardiography, whereas CT is more accurate than
Left Ventricular Function Parameters inthe 7 Patients Who Underwent CE Echocardiography
Table 1
Left Ventricul r Function Parameters in
the 7 Patients Who Underwent CE Echocardiography
MRI CT 2D Echo 2D CE Echo
EF, % 61.5 5.3 62.7 9.9 61.6 9.9 65.5 4.6
EDV, ml 116.5 29.0 126.0 33.3* 81.4 29.4* 94.2 25.9*
ESV, ml 45.7 16.5 47.4 18.8 31.3 12.0* 32.2 9.4*
SV, ml 70.8 14.3 78.6 25.2 50.1 20.3 62.0 18.4
*p  0.05, Wilcoxon test versus MRI.
CE  contrast enhanced; CT  computed tomography; Echo  echocardiography; EDV 
nd-diastolic volume; EF  ejection fraction; ESV  end-systolic volume; MRI  magnetic
esonance imaging; SV  stroke volume; 2D  two-dimensional.
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Dysglycemia and
Cardiovascular Risk
I read with interest the “state-of-the art” paper by Grundy (1) that
was recently published in the Journal. The paper demonstrated that
the pre-diabetic range of glucose levels do not directly cause
atherosclerosis or its complications, on the basis of a systemic
review of the relationship between pre-diabetes and cardiovascular
disease (CVD). The paper also indicated that the major targets for
the prevention of CVD are elevations of cholesterol and blood
pressure, but not elevations of plasma glucose, because certain
clinical trials have suggested that the glucose-lowering drugs did
not retard atherogenesis. My question is whether it is in fact
reasonable to exclude the clinical worth of lowering glucose,
especially in postprandial hyperglycemia, for the prevention of
CVD in subjects with pre-diabetes.
Both epidemiological and interventional studies have shown
that pre-diabetes, especially in post-prandial hyperglycemia, is a
direct and independent risk factor for CVD (2–4). In the
DECODE (Diabetes Epidemiology: Collaborative Analysis of
Diagnostic Criteria in Asia) study, the risk for CVD and stroke
increased progressively with the change from impaired fasting
glucose to impaired glucose tolerance (IGT) to type 2 diabetes (5),
indicating that hyperglycemia is a risk factor for cardiovascular(CV) mortality. The relation between glycemia and CV risk
started within the normal blood glucose range, with a linear
relationship (4,5). In addition, post-challenge hyperglycemia is
strongly associated with future macrovascular events and total
mortality in patients with acute myocardial infarction and/or
patients with coronary disease who received angiography (6).
The results of the STOP-NIDDM (Study to Prevent Non-
Insulin-Dependent Diabetes Mellitus) trial demonstrated that
treating IGT with acarbose, an alpha-glucosidase inhibitor, which
specifically reduces postprandial hyperglycemia, significantly re-
duces the conversion rate of IGT to type 2 diabetes associated with
reductions in the development of CV events (by 49%), the
incidence of new cases of hypertension (by 34%) (7), and the
annual increase of carotid intima–media thickness (by 50%) (8).
Moreover, pioglitazone significantly reduces diastolic blood pres-
sure and the rate of the intima–media thickness associated with a
reduction in the conversion of IGT to type 2 diabetes (9).
Thus, dysglycemia, especially in the case of postprandial hyper-
glycemia, is related to CV risk and mortality, and a variety of
pharmacological and nonpharmacological therapies should be
targeted to the management of postprandial blood glucose inde-
pendent of blood pressure and/or cholesterol.
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